tiprankstipranks
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
US Market
RAPP
Rapport Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see RAPP full AI Analyst Report?

Rapport Therapeutics, Inc. (RAPP) Stock News & Sentiment

144 Followers
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
Premium
Ratings
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
9d ago
RAPP
Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile
Premium
Ratings
Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile
20d ago
RAPP
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market
Premium
Company Announcements
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market
20d ago
RAPP
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
Premium
Company Announcements
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
1M ago
8K
RAPP
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
Premium
Ratings
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
3M ago
RAPP
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
Premium
Company Announcements
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
4M ago
RAPP
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating
Premium
Ratings
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating
5M ago
RAPP
More RAPP News >

RAPP News on the Web

Rapport Therapeutics price target raised to $65 from $53 at BTIG
TipRanks News
Bullish
Rapport Therapeutics, Inc. (RAPP) Receives a Buy from BTIG
TipRanks News
Bullish
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT)
TipRanks News
Bullish
Johnson & Johnson Reduces Stake in Rallybio Corp: A Strategic Portfolio Adjustment
GuruFocus News
Neutral
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Therapeutics Inc (RAPP)
GuruFocus News
Neutral
Closing Bell Movers: Markets on edge ahead of US-Iran talks
TipRanks News
Bullish
Rapport Therapeutics initiated with a Strong Buy at Raymond James
TipRanks News
Neutral
Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therapeutics Inc (RAPP)
GuruFocus News
Neutral

News Score - Last 7 Days

Very Positive
RAPP
Sector Average
Media Buzz
This Week2 articles
Weekly Average2 articles
News Sentiment
This Week99%
Sector Average79%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is RAPP’s Media Buzz Sentiment?
2 articles about RAPP were published this week. In an average week, 2 articles are published.
    What is RAPP’s weekly average amount of articles?
    In an average week, 2 articles about RAPP are published.
      What is RAPP’s News Sentiment?
      99% of articles about RAPP were positive this week, compared to its sector average of 79%.
        Healthcare Stocks that are Trending in the News
        AKTXAkari Therapeutics
        IMMXImmix Biopharma
        SYSo-Young International
        ADOAnteoTech Ltd
        FSPKFFisher & Paykel Healthcare Corporation Limited
        Showing the stocks with the most bullish news sentiment over the past week